- Home
- NCNA vs CHEK Comparison
NCNA vs CHEK Comparison
Compare NCNA & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- CHEK
- Stock Information
- Founded
- NCNA 1997
- CHEK 2004
- Country
- NCNA United Kingdom
- CHEK Israel
- Employees
- NCNA N/A
- CHEK N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- NCNA Health Care
- CHEK Health Care
- Exchange
- NCNA Nasdaq
- CHEK Nasdaq
- Market Cap
- NCNA 4.5M
- CHEK 4.0M
- IPO Year
- NCNA 2017
- CHEK 2015
- Fundamental
- Price
- NCNA $0.65
- CHEK $0.67
- Analyst Decision
- NCNA Buy
- CHEK
- Analyst Count
- NCNA 2
- CHEK 0
- Target Price
- NCNA $25.00
- CHEK N/A
- AVG Volume (30 Days)
- NCNA 140.2K
- CHEK 22.2K
- Earning Date
- NCNA 05-15-2025
- CHEK 05-14-2025
- Dividend Yield
- NCNA N/A
- CHEK N/A
- EPS Growth
- NCNA N/A
- CHEK N/A
- EPS
- NCNA N/A
- CHEK N/A
- Revenue
- NCNA N/A
- CHEK N/A
- Revenue This Year
- NCNA N/A
- CHEK N/A
- Revenue Next Year
- NCNA N/A
- CHEK N/A
- P/E Ratio
- NCNA N/A
- CHEK N/A
- Revenue Growth
- NCNA N/A
- CHEK N/A
- 52 Week Low
- NCNA $0.69
- CHEK $0.56
- 52 Week High
- NCNA $10.79
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- NCNA 39.85
- CHEK 41.37
- Support Level
- NCNA $0.71
- CHEK $0.64
- Resistance Level
- NCNA $0.89
- CHEK $0.71
- Average True Range (ATR)
- NCNA 0.09
- CHEK 0.06
- MACD
- NCNA -0.00
- CHEK 0.00
- Stochastic Oscillator
- NCNA 12.68
- CHEK 31.06
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.